Advertisement
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Cell Therapeutics to Appeal FDA's NDA Decision

September 14, 2010 6:48 am | News | Comments

Cell Therapeutics, Inc. intends to appeal the FDA's decision to require an additional clinical trial for pixantrone to treat patients with relapsed/refractory aggressive non-Hodgkin's lymphoma.

TOPICS:

Drug-resistant Superbugs Found in 3 States

September 14, 2010 6:42 am | by Marilnn Marchione, AP Medical Writer | News | Comments

Bacteria that have been made resistant to nearly all antibiotics by an alarming new gene have sickened people in three states and are popping up all over the world, health officials reported.

TOPICS:

Repeated Antibiotics Alter Beneficial Gut Germs

September 14, 2010 6:23 am | by Lauran Neergaard, AP Medical Writer | News | Comments

Antibiotics can temporarily upset your stomach, but now it turns out that repeatedly taking them can trigger long-lasting changes in all those good germs that live in your gut.

TOPICS:
Advertisement

HPLC Column

September 13, 2010 10:37 am | Product Releases | Comments

Thermo Fisher Scientific Inc. has announced the Syncronis HPLC column range. This new range unerringly delivers consistent, predictable separations, from run to run and column to column.

TOPICS:

Microplate Dispenser

September 13, 2010 9:15 am | Drug Discovery & Development | Product Releases | Comments

BioTek’s MultiFlo Microplate Dispenser uses multiple technologies to dispense multiple reagents into multiple microplate types. This all-in-one dispenser saves bench space and transfer time, and also eliminates plate setup steps.

TOPICS:

Forest Labs Files Response to FDA Letter

September 13, 2010 8:59 am | News | Comments

Nycomed announced that its US partner Forest Laboratories, Inc. has filed a response to the FDA addressing topics raised in the complete response letter regarding the New Drug Application for roflumilast (Daxas).

TOPICS:

Cyclacel Reaches Agreement With FDA

September 13, 2010 8:53 am | News | Comments

Cyclacel Pharmaceuticals Inc. said it has reached a deal with the Food and Drug Administration on a design for a late-stage study of a potential cancer treatment and plans to begin patient enrollment before the end of 2010.

TOPICS:

Mystery of Protein Quality Control Unraveled

September 13, 2010 8:39 am | News | Comments

Scientists have solved a long-standing mystery of how cells conduct "quality control" to eliminate the toxic effects of a certain kind of error in protein production. The findings may lead to a better understanding of a host of neurodegenerative diseases.

TOPICS:
Advertisement

Gene Discovery Could Yield Treatment for Nearsightedness

September 13, 2010 8:37 am | News | Comments

Scientists at Duke University Medical Center, in conjunction with several other groups, have uncovered a gene associated with myopia in Caucasian people from several different regions, including Dutch, British and Australian subjects.

TOPICS:

Melanoma Drug Data to Be Presented At IMRC

September 13, 2010 8:15 am | News | Comments

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announces that data from its Phase 2 PV-10 metastatic melanoma study will be presented at the International Melanoma Research Congress.

TOPICS:

Phase 2 Studies Confirm Radezolid Effectiveness

September 13, 2010 8:09 am | News | Comments

Rib-X Pharmaceuticals, Inc., a development-stage antibiotics company with a broad product pipeline based on its innovative discovery platform, announced the presentation of positive preclinical data for radezolid at the Interscience Conference on Antimicrobial Agents and Chemotherapy.

TOPICS:

LabCorp to Buy Genzyme Genetic Testing Business

September 13, 2010 8:04 am | News | Comments

Genzyme Corp. said that it is selling its genetic testing business to Laboratory Corp. of America Holdings for $925 million so it can focus on its core growth areas.

TOPICS:

FDA Considers Pulling Dangerous Diet Pill

September 13, 2010 8:01 am | by Matthew Perrone | News | Comments

Almost a year after studies showed the diet pill Meridia increases heart attack and stroke risk, U.S. health regulators announced they will consider pulling the Abbott Laboratories' drug off the market.

TOPICS:

Limber LIMS

September 13, 2010 7:57 am | Articles | Comments

A range of Web-based tools are bringing automated management to more labs.

TOPICS:

DDI Reality via Virtual Studies

September 13, 2010 7:41 am | by Steve Toon, PhD; Executive Director; Elizabeth Kingsley, PhD; PR Coordinator; Simcyp Limited; Sheffield, UK | Articles | Comments

Simulation of drug-drug interactions anticipate in vivo outcomes.

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading